The current status of checkpoint inhibitors in metastatic bladder cancer
For many decades, no significant improvements could be achieved to prolong the survival in metastatic bladder cancer. Recently, systemic immunotherapy with checkpoint inhibitors (anti-PD-L1/anti-CTLA-4) has been introduced as a novel treatment modality for patients with metastatic bladder cancer. We...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Verlag
2016
|
| Online Access: | http://psasir.upm.edu.my/id/eprint/52960/ http://psasir.upm.edu.my/id/eprint/52960/1/The%20current%20status%20of%20checkpoint%20inhibitors%20in%20metastatic%20bladder%20cancer.pdf |
| _version_ | 1848852183896817664 |
|---|---|
| author | Fahmy Ahmed, Omar Ahmed Mohd. Ghani @ Mamat, Khairul Asri Stenzl, Arnulf Gakis, Georgios |
| author_facet | Fahmy Ahmed, Omar Ahmed Mohd. Ghani @ Mamat, Khairul Asri Stenzl, Arnulf Gakis, Georgios |
| author_sort | Fahmy Ahmed, Omar Ahmed |
| building | UPM Institutional Repository |
| collection | Online Access |
| description | For many decades, no significant improvements could be achieved to prolong the survival in metastatic bladder cancer. Recently, systemic immunotherapy with checkpoint inhibitors (anti-PD-L1/anti-CTLA-4) has been introduced as a novel treatment modality for patients with metastatic bladder cancer. We conducted a systematic review according to the PRISMA statement for data published on the clinical efficacy of checkpoint inhibitors in metastatic bladder cancer. Clinical efficacy of anti PD-L1 therapy was investigated in prospective trials in a total of 155 patients. Patients with positive expression for PD-L1 tended towards better overall response rates (ORR) compared to those with negative expression (34/76 vs 10/73, 45 vs 14 %; p = 0.21). Among patients with PD-L1 positive tumors, those with non-visceral metastases exhibited significantly higher ORR compared to those with visceral metastases (82 vs 28 %; p = 0.001). For anti-CTLA4 therapy, there were no data retrievable on clinical efficacy. Although data on clinical efficacy of checkpoint inhibitors in metastatic bladder cancer are currently limited, the efficacy of these drugs might depend mainly on the metastatic volume and immune system integrity. Patients with PD-L1 positive tumors and non-visceral metastases seem to derive the highest benefit from therapy. |
| first_indexed | 2025-11-15T10:34:02Z |
| format | Article |
| id | upm-52960 |
| institution | Universiti Putra Malaysia |
| institution_category | Local University |
| language | English |
| last_indexed | 2025-11-15T10:34:02Z |
| publishDate | 2016 |
| publisher | Springer Verlag |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | upm-529602018-04-30T13:36:55Z http://psasir.upm.edu.my/id/eprint/52960/ The current status of checkpoint inhibitors in metastatic bladder cancer Fahmy Ahmed, Omar Ahmed Mohd. Ghani @ Mamat, Khairul Asri Stenzl, Arnulf Gakis, Georgios For many decades, no significant improvements could be achieved to prolong the survival in metastatic bladder cancer. Recently, systemic immunotherapy with checkpoint inhibitors (anti-PD-L1/anti-CTLA-4) has been introduced as a novel treatment modality for patients with metastatic bladder cancer. We conducted a systematic review according to the PRISMA statement for data published on the clinical efficacy of checkpoint inhibitors in metastatic bladder cancer. Clinical efficacy of anti PD-L1 therapy was investigated in prospective trials in a total of 155 patients. Patients with positive expression for PD-L1 tended towards better overall response rates (ORR) compared to those with negative expression (34/76 vs 10/73, 45 vs 14 %; p = 0.21). Among patients with PD-L1 positive tumors, those with non-visceral metastases exhibited significantly higher ORR compared to those with visceral metastases (82 vs 28 %; p = 0.001). For anti-CTLA4 therapy, there were no data retrievable on clinical efficacy. Although data on clinical efficacy of checkpoint inhibitors in metastatic bladder cancer are currently limited, the efficacy of these drugs might depend mainly on the metastatic volume and immune system integrity. Patients with PD-L1 positive tumors and non-visceral metastases seem to derive the highest benefit from therapy. Springer Verlag 2016 Article PeerReviewed text en http://psasir.upm.edu.my/id/eprint/52960/1/The%20current%20status%20of%20checkpoint%20inhibitors%20in%20metastatic%20bladder%20cancer.pdf Fahmy Ahmed, Omar Ahmed and Mohd. Ghani @ Mamat, Khairul Asri and Stenzl, Arnulf and Gakis, Georgios (2016) The current status of checkpoint inhibitors in metastatic bladder cancer. Clin Exp Metastasis, 33 (7). pp. 629-635. ISSN 0262-0898; ESSN: 1573-7276 10.1007/s10585-016-9807-9 |
| spellingShingle | Fahmy Ahmed, Omar Ahmed Mohd. Ghani @ Mamat, Khairul Asri Stenzl, Arnulf Gakis, Georgios The current status of checkpoint inhibitors in metastatic bladder cancer |
| title | The current status of checkpoint inhibitors in metastatic bladder cancer |
| title_full | The current status of checkpoint inhibitors in metastatic bladder cancer |
| title_fullStr | The current status of checkpoint inhibitors in metastatic bladder cancer |
| title_full_unstemmed | The current status of checkpoint inhibitors in metastatic bladder cancer |
| title_short | The current status of checkpoint inhibitors in metastatic bladder cancer |
| title_sort | current status of checkpoint inhibitors in metastatic bladder cancer |
| url | http://psasir.upm.edu.my/id/eprint/52960/ http://psasir.upm.edu.my/id/eprint/52960/ http://psasir.upm.edu.my/id/eprint/52960/1/The%20current%20status%20of%20checkpoint%20inhibitors%20in%20metastatic%20bladder%20cancer.pdf |